Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

Dompé advanced cenegermin-bkbj into Phase 3 for NAION, a rapid vision-loss condition with no FDA-approved treatment options. The move into Phase 3 is a positive clinical development milestone that could improve the therapy’s probability of eventual regulatory approval.

Analysis

Dompé advanced cenegermin-bkbj into Phase 3 for NAION, a rapid vision-loss condition with no FDA-approved treatment options. The move into Phase 3 is a positive clinical development milestone that could improve the therapy’s probability of eventual regulatory approval.